- Home
- SKYE vs CNF Comparison
SKYE vs CNF Comparison
Compare SKYE & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKYE | CNF |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 19.5M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SKYE | CNF |
|---|---|---|
| Price | $0.83 | $2.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 198.7K | 3.3K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $252.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.37 |
| 52 Week High | $5.75 | $24.00 |
Technical Indicators
Market Signals| Indicator | SKYE | CNF |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 37.10 |
| Support Level | $0.68 | $2.72 |
| Resistance Level | $1.15 | $3.60 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 30.98 | 20.02 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.